Trials & Filings

Rexahn Begins Solid Tumor Trial

Ph Ib trial to study safety, efficacy with dose-escalation over cycle

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Rexahn Pharmaceuticals has initiated a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors. The trial is a multi-center dose-escalation study that will evaluate the safety, tolerability, dose-limiting toxicities and maximal tolerated dose (MTD) of RX-3117 in patients with solid tumors. Secondary endpoints will include characterizing the pharmacokinetic profile of RX-3117 and evaluating the preliminary anti-tumor effects of RX-3117. RX-3117 is...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters